Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket

Author: Avi Kapoor | March 25, 2024 08:03am

Shares of Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) rose sharply in today’s pre-market trading following fourth-quarter results.

Salarius Pharmaceuticals posted a net loss of $0.9 million, or 22 cents per share for the fourth quarter, narrower than the year-ago loss of $6.4 million, or $2.83 per share, according to data from Benzinga Pro.

Salarius Pharmaceuticals shares jumped 31.4% to $0.8149 in pre-market trading

Here are some other stocks moving in pre-market trading.

Gainers

  • Next.e.GO N.V. (NASDAQ:EGOX) shares rose 85.8% to $0.0730 in pre-market trading after falling around 22% on Friday.
  • MicroAlgo Inc. (NASDAQ:MLGO) rose 56.7% to $6.30 in pre-market trading after declining around 5% on Friday.
  • Forge Global Holdings, Inc. (NYSE:FRGE) shares gained 22.8% to $2.86 in pre-market trading after gaining 13% on Friday.
  • Canopy Growth Corporation (NASDAQ:CGC) gained 19.5% to $9.17 in pre-market trading. The German government approved legislation which legalizes the possession and cultivation of cannabis beginning April 1.
  • Flora Growth Corp. (NASDAQ:FLGC) shares rose 17.7% to $1.86 in pre-market trading after surging around 34% on Friday.
  • Cazoo Group Ltd (NASDAQ:CZOO) gained 17.3% to $4.35 in pre-market trading after declining around 21% on Friday.
  • Biophytis S.A. (NASDAQ:BPTS) climbed 17.1% to $0.4471 in pre-market trading. Biophytis recently presented its Phase 3 protocol of RuvembriTM in the treatment of Sarcopenia at the ICFSR.
  • Recon Technology, Ltd. (NASDAQ:RCON) shares rose 14.5% to $0.1570 in pre-market trading.
  • Esperion Therapeutics, Inc. (NASDAQ:ESPR) gained 12.7% to $2.58 in pre-market trading as the U.S. FDA approved broad new labels for Esperion's NEXLETOL® and NEXLIZET® to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use.

Losers

  • Sintx Technologies, Inc. (NASDAQ:SINT) dipped 29.7% to $0.0650 in pre-market trading. SINTX Technologies shares dipped 32% on Friday after the company announced a proposed public offering of common stock.
  • Invivyd, Inc. (NASDAQ:IVVD) declined 14.8% to $3.72 in pre-market trading. Invivyd shares jumped 41% on Friday after the company announced that PEMGARDA received emergency use authorization from the FDA for the pre-exposure prophylaxis of COVID-19.
  • Greenlane Holdings, Inc. (NASDAQ:GNLN) fell 10.8% to $0.52 pre-market trading after jumping around 11% on Friday.
  • BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) fell 10.8% to $2.24 pre-market trading after dipping 31% on Friday.
  • Mangoceuticals, Inc. (NASDAQ:MGRX) shares tumbled 9.7% to $0.1688 in pre-market trading after declining around 5% on Friday.
  • Australian Oilseeds Holdings Limited (NASDAQ:COOT) fell 8.5% to $2.27 in pre-market trading after falling over 22% on Friday.
  • Ontrak, Inc. (NASDAQ:OTRK) fell 8.2% to $0.36 in pre-market trading after jumping around 50% on Friday.
  • Murano Global Investments Plc (NASDAQ:MRNO) shares fell 7.6% to $19.64 in pre-market trading amid volatility following the company's recently completed business combination with HCM Acquisition Corp and Nasdaq debut last week.
  • Laser Photonics Corporation (NASDAQ:LASE) shares fell 6.5% to $1.73 in pre-market trading after dipping around 9% on Friday. Laser Photonics, last week, announced a distribution agreement with Incredible Supply & Logistics (ISL) for its military and industrial laser solutions.
  • OKYO Pharma Limited (NASDAQ:OKYO) shares tumbled 6.2% to $1.44 after falling around 13% on Friday. OKYO Pharma, last week, announced additional key findings from analyses of the clinical data set from the 240-patient Phase 2 trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED).

 

Now Read This: Top 5 Consumer Stocks That May Crash This Month

Posted In: BCAN BPTS CGC COOT CZOO EGOX ESPR FLGC FRGE GNLN IVVD LASE MGRX MLGO MRNO OKYO OTRK RCON SINT SLRX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist